Dr. Reddy's Laboratories Ltd. (RDY)
12.49
+0.17
(+1.38%)
USD |
NYSE |
Oct 06, 16:00
12.35
-0.14
(-1.12%)
Pre-Market: 08:39
Dr. Reddy's Laboratories Enterprise Value : 10.34B for Oct. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 06, 2026 | 10.34B |
| October 05, 2026 | 10.20B |
| October 02, 2026 | 10.14B |
| October 01, 2026 | 10.14B |
| September 30, 2026 | 10.45B |
| September 29, 2026 | 10.64B |
| September 28, 2026 | 10.36B |
| September 25, 2026 | 10.14B |
| September 24, 2026 | 10.18B |
| September 23, 2026 | 10.26B |
| September 22, 2026 | 10.41B |
| September 21, 2026 | 10.26B |
| September 18, 2026 | 10.09B |
| September 17, 2026 | 10.09B |
| September 16, 2026 | 9.664B |
| September 15, 2026 | 9.556B |
| September 14, 2026 | 9.856B |
| September 11, 2026 | 9.847B |
| September 10, 2026 | 9.689B |
| September 09, 2026 | 9.831B |
| September 08, 2026 | 9.831B |
| September 04, 2026 | 9.906B |
| September 03, 2026 | 9.956B |
| September 02, 2026 | 10.07B |
| September 01, 2026 | 10.07B |
| Date | Value |
|---|---|
| August 31, 2026 | 10.04B |
| August 28, 2026 | 10.08B |
| August 27, 2026 | 10.06B |
| August 26, 2026 | 10.11B |
| August 25, 2026 | 10.21B |
| August 24, 2026 | 10.11B |
| August 21, 2026 | 10.08B |
| August 20, 2026 | 10.02B |
| August 19, 2026 | 10.02B |
| August 18, 2026 | 10.06B |
| August 17, 2026 | 10.02B |
| August 14, 2026 | 10.16B |
| August 13, 2026 | 10.28B |
| August 12, 2026 | 10.26B |
| August 11, 2026 | 10.31B |
| August 10, 2026 | 10.06B |
| August 07, 2026 | 10.11B |
| August 06, 2026 | 10.02B |
| August 05, 2026 | 10.05B |
| August 04, 2026 | 10.01B |
| August 03, 2026 | 9.989B |
| July 31, 2026 | 9.806B |
| July 30, 2026 | 9.789B |
| July 29, 2026 | 9.731B |
| July 28, 2026 | 9.706B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Takeda Pharmaceutical Co., Ltd. | 84.77B |
| Teva Pharmaceutical Industries Ltd. | 58.81B |
| Novo Nordisk A/S | 140.12B |
| AstraZeneca PLC | 518.25B |
| ANI Pharmaceuticals, Inc. | 1.878B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 45.92M |
| Revenue (Quarterly) | 852.30M |
| Total Expenses (Quarterly) | 805.46M |
| EPS Diluted (Quarterly) | 0.0562 |
| Gross Profit Margin (Quarterly) | 42.70% |
| Profit Margin (Quarterly) | 5.39% |
| Earnings Yield | 3.56% |
| Operating Earnings Yield | 3.54% |